Player FM uygulamasıyla çevrimdışı Player FM !
New Evidence With BTK Inhibitor Therapy in MCL From ICML 2023
Manage episode 374542196 series 3256997
In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of:
- Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL
- BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
- IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL
Presenters:
Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California
Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
183 bölüm
Manage episode 374542196 series 3256997
In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of:
- Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL
- BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
- IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL
Presenters:
Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California
Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
183 bölüm
Alle Folgen
×Player FM'e Hoş Geldiniz!
Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.